Pacira BioSciences Completes Viatris Merger, Revises Notes and Ends Credit Facility
Pacira BioSciences (PCRX) completed its merger with Viatris, revising its $287.5M convertible notes to reflect the $36.50-per-share cash consideration, unwinding capped call transactions, and repaying $96,392.50 to terminate its credit facility with Wells Fargo.
How this was made

The 30-second read
Why it matters
Amending conversion terms to match the merger’s $36.50-per-share cash consideration and terminating the credit facility should reduce refinancing risk and simplify the post-merger capital stack.
Market read
This is a post-merger financing and hedging unwind that can affect convertible pricing, equity risk, and near-term hedging flows.
What to watch
Traders may need to monitor how the amended conversion terms and capped call unwind affect near-term hedging flows and convertible arbitrage positioning, which the article does not quantify.
Background
Pacira completed its merger with Viatris and used the closing to restructure related financing instruments.
Ticker impact
Pacira BioSciences completed its Viatris merger and amended $287.5M convertible notes, unwound capped calls, and repaid/terminated its credit facility.
Likely modest positive bias as the market prices lower leverage and clearer note conversion terms post-merger.
The article discloses multiple balance-sheet actions (note amendment, capped call unwind, credit facility termination) with explicit linkage to the merger consideration, but it does not provide incremental operating guidance or a new deal price change beyond the stated $36.50 cash consideration.
Market effects
Biopharma capital-structure refinancing around M&A can influence sentiment toward other deal-linked issuers and convertible-note liquidity.
Primarily US credit and equity microstructure effects for the issuer’s convertibles and hedging counterparties.
Limited, as the disclosed actions are company-specific and not a cross-market policy or sector-wide shock.
Counterpoint
The actions may be largely mechanical post-merger (conversion term alignment, capped call unwind, credit payoff), so equity impact could be muted versus the market’s prior expectations for the merger.
Key entities
- companyPacira BioSciences
Issuer that amended convertible notes, unwound capped calls, and repaid/terminated its credit agreement after completing the Viatris merger.
- companyViatris
Counterparty in the merger whose cash consideration is referenced in the note conversion amendment.
- financial_institutionWells Fargo Bank
Credit agreement counterparty that is repaid and whose facility is terminated.
- trusteeComputershare Trust Company
Counterparty for the supplemental indenture amending the convertible notes.
